The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2/3 study of Bicycle toxin conjugate BT8009 targeting nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC): Duravelo-2.
 
Yohann Loriot
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; Janssen; Loxo/Lilly; Merck KGaA; MSD Oncology; MSD Oncology (Inst); Pfizer (Inst); Pfizer/EMD Serono; Roche; Roche (Inst); Seagen; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); BMS (Inst); Exelixis (Inst); Gilead Sciences (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tyra Biosciences (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen
 
Arlene O. Siefker-Radtke
Consulting or Advisory Role - AstraZeneca; Basilea Pharmaceutical; Bavarian Nordic; Bristol-Myers Squibb; G1 Therapeutics; Genentech; Gilead Sciences; Ideeya Biosciences; Immunomedics; Janssen; Loxo; Merck; Mirati Therapeutics; NCCN; Nektar; Seagen; Taiho Pharmaceutical
Research Funding - Basilea (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Merck (Inst); Nektar (Inst); NIH (Inst)
Patents, Royalties, Other Intellectual Property - Methods of characterizing and treating molecular subsets of muscle-invasive bladder cancer.
 
Terence W. Friedlander
Leadership - Med BioGene
Honoraria - Astellas Pharma; Astellas Scientific and Medical Affairs Inc; AstraZeneca/MedImmune; EMD Serono
Consulting or Advisory Role - AADi; Astellas Pharma; Basilea; Dava Oncology; EMD Serono; Foundation Medicine; Merck; Seagen; Taiho Oncology
Research Funding - Bristol-Myers Squibb; Neon Therapeutics; Roche/Genentech; Seagen
Travel, Accommodations, Expenses - Astellas Pharma; Astellas Pharma; AstraZeneca/MedImmune; EMD Serono; Jounce Therapeutics
 
Andrea Necchi
Employment - Bayer (I)
Stock and Other Ownership Interests - Bayer (I)
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Foundation Medicine; Janssen; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Catalym; Genenta Science; Gilead Sciences; Incyte; Janssen; Merck Sharp & Dohme; Roche; Seattle Genetics/Astellas
Research Funding - AstraZeneca (Inst); Gilead Sciences (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Sharp & Dohme
 
Alexander Z Wei
Research Funding - IDEAYA Biosciences (Inst); Novartis (Inst); Pyxis (Inst); Regeneron (Inst)
 
Srikala S. Sridhar
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Gilead Sciences (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Seagen (Inst)
Research Funding - Bayer (Inst); Janssen (Inst); Pfizer (Inst)
 
Benjamin Garmezy
Research Funding - Abbvie (Inst); Abbvie (Inst); Accutar Biotech (Inst); Arcus Biosciences (Inst); Arcus Biosciences (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); crispr therapeutics (Inst); Envision Pharma Group (Inst); Exelixis (Inst); Genentech (Inst); Harbour BioMed (Inst); IDEAYA Biosciences (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Jubilant Therapeutics (Inst); Kineta (Inst); Kineta (Inst); Kinnate Biopharma (Inst); Loxo (Inst); Loxo/Lilly (Inst); MiNK Therapeutics (Inst); Nuvation Bio (Inst); ProfoundBio (Inst); Roche/Genentech (Inst); Teon Therapeutics (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst); Xencor (Inst); Zenshine (Inst); Zenshine (Inst)
(OPTIONAL) Uncompensated Relationships - Abbvie (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arvinas (Inst); AVEO (Inst); Bayer (Inst); Eisai (Inst); Exelixis (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst)
 
Santiago Arroyo
Employment - Bicycle Therapeutics
Leadership - Bicycle Therapeutics
Stock and Other Ownership Interests - Bicycle Therapeutics
Honoraria - Bicycle Therapeutics
Consulting or Advisory Role - Bicycle Therapeutics
Patents, Royalties, Other Intellectual Property - Bicycle Therapeutics
Travel, Accommodations, Expenses - Bicycle Therapeutics
 
Emma Gartside
Employment - Bicycle Therapeutics, Roche Products Ltd
Stock and Other Ownership Interests - Roche
 
Jie Liu
Employment - Bicycle Therapeutics
 
Carly Campbell
Employment - Bicycle Therapeutics
Stock and Other Ownership Interests - Bicycle Therapeutics; Epizyme
 
Justin Bader
Employment - Bicycle Therapeutics
Stock and Other Ownership Interests - Bicycle Therapeutics
 
Daniel P. Petrylak
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Gilead Sciences; Incyte; Ipsen; Janssen; Lilly; Mirati Therapeutics; Monopteros Therapeutics; Pfizer; Pharmacyclics; Regeneron; Roche; Seagen; Urogen pharma
Research Funding - Advanced Accelerator Applications (Inst); Agensys (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Endocyte (Inst); Genentech (Inst); Gilead Sciences (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Replimune (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)
Expert Testimony - Celgene; sanofi